Citi initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $16 price target Wave is a clinical-staged biotech company developing a pipeline of RNA medicines for rare and common diseases, the analyst tells investors in a research note. The firm sees several near-term data catalysts for Wave with potential for upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating
- Wave Life Sciences: Promising RNA Editing Developments and Positive Stock Outlook
- Wave Life Sciences’ WVE-007: Undervalued Potential in Obesity Treatment with Promising Preclinical Results
- Wave Life Sciences assumed with an Outperform at Raymond James
- Wave Life Sciences announces appointment of Wright as CMO